CM101 stimulates cutaneous wound healing through an anti-angiogenic mechanism

Angiogenesis

Volumn 4, Issue 1, 2001, Pages 61-70

  Nanney, Lillian B ^a   Wamil, Barbara D ^a   Whitsitt, Jeffrey ^a   Cardwell, Nancy L ^a   Davidson, Jeffrey M ^a   Yan, He Ping ^a   Hellerqvist, Carl G ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; CM101; Endothelium; Laser doppler perfusion; Wound healing

Indexed keywords

ANGIOGENESIS INHIBITOR; CM 101;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; DOSE RESPONSE; DRUG ISOLATION; DRUG MECHANISM; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; NONHUMAN; PERFUSION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SCAR FORMATION; STREPTOCOCCUS AGALACTIAE; WOUND HEALING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GRANULATION TISSUE; INFLAMMATION; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE; MICROCIRCULATION; NEOVASCULARIZATION, PHYSIOLOGIC; ORGANIC ANION TRANSPORTERS; POLYSACCHARIDES, BACTERIAL; SKIN; SKIN PHYSIOLOGY; SWINE; SYMPORTERS; WOUND HEALING;

ANIMALIA; STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS SP. 'GROUP B'; SUS SCROFA;

EID: 0035679574     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016752925761     Document Type: Article

References (47)

1. Role of leukocytes and endothelial cells in the development of angiogenesis in inflammation and wound healing
2. Angiogenesis in wound healing
3. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
4. Angiogenesis: Mechanistic insights, neovascular diseases, and therapeutic approaches
5. Angiogenesis and angiogenic inhibition: An overview
6. Factors controlling ocular angiogenesis
7. Activation of vascular endothelial growth factor gene transcription by Hypoxia-Inducible Factor 1
8. Molecular mechanisms of blood vessel formation
9. Angiogenesis in cancer and other diseases
10. Fibrogenic cytokines and connective tissue production
11. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice
12. Angiogenesis and the skin: A primer
13. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing
14. Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene
15. Transforming growth factor-beta stimulates wound healing and modulates extracellular matrix gene expression in pig skin. I. Excisional wound model
16. Assessment of differential cytokine effects on angiogenesis using an in vivo model of cutaneous wound repair
17. Basic fibroblast growth factor mediates angiogenic activity in early surgical wounds
18. Manipulation of the wound-healing process with basic fibroblast growth factor
19. Platelet-derived growth factor (BB homidimer), transforming growth factor-beta 1, and basic fibroblast growth factor in dermal wound healing. Neovessel and matrix formation and cessation of repair
20. Age-dependent impairment of angiogenesis
21. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2
22. Neovascularization in aged mice: Delayed angiogenesis is coincident with decreased levels of transforming growth factor beta-1 and type I collagen
23. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF
24. Impaired wound repair and delayed angiogenesis in aged mice
25. Impaired wound healing and angiogenesis in iNOS-deficient mice
26. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing
27. The pathophysiology of angiogenesis
28. Isolation and identification of a group b β-hemolytic streptococcal toxin from septic infants
29. Studies on Group B β-hemolytic streptococcus. I. Isolation and partial characterization of an extracellular toxin
30. Identification and characterization of HP59: A unique pathoangiogenic marker targeted by CM101
31. Functional studies on the antipathoangiogenic properties of CM101
32. Soluble e-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial
33. Phase I study of the antineovascularization drug CM101
34. CM101, a polysaccharide anti-tumor agent, does not inhibit wound healing in murine models
35. Mapping neovascularization and anti-neovascularization therapy: Correlation between NMR and light microscopy
36. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells
37. Comparisons of wound healing among excisional, laser-created, and standard thermal burns in porcine wounds of equal depth
38. Epidermal and dermal effects of epidermal growth factor during porcine wound repair
39. Boosting of EGF receptorsa by gene gun stimulates epidermal growth in vivo
40. Anti-tumor effects of GBS toxin: A polysaccharide exotoxin from group B b-hemolytic streptococcus
41. Detection of circulating antigen in human schistosomiasis japonica using monoclonal antibody
42. Fibrin and collagen differentially regulate human dermal microvascular endothelial cell integrins: Stabilization of alphav/beta3 mRNA by fibrin 1
43. Role of alpha(v) integrins and angiogenesis during wound repair
44. CM101-mediated recovery of walking ability in adult mice paralyzed by spinal cord injury
45. Effects of GBS toxin on long-term survival of mice bearing transplanted Madison lung tumors
46. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing